YOLFTbeta
04

Panagene Inc

046210 · KQ · Healthcare / Biotechnology & Medical Research

1,019.00KRW-39.00 (-3.69%)

Price History

Full chart

Market Stats

Previous Close1,058.00
Open1,061.00
Day Range1,011.00 – 1,066.00
52-Week Range980.00 – 2,940.00
Volume105.65K
Market Cap55.84B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.83
50-Day Avg1,134.06
200-Day Avg1,652.51

About

Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The company was formerly known as Koram Panagene Ltd. and changed its name to Panagene Inc. in January 2009. Panagene Inc. was incorporated in 1976 and is based in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology & Medical Research
  • CEOByung-Hoon Lee
  • Employees63
  • Headquarters54, Techno 10-ro, Daejeon, South Korea, 34027, Korea
  • Websitehttps://www.panagene.com

Leadership

  • Byung-Hoon LeeManaging Director · b. 1954
  • Tae-Sung KimManaging Director · b. 1965
  • Goon-Ho ChoExec.
  • Sang-Yong ParkExec. · b. 1965
  • Sung-Ki KimChief Exec. Officer and Pres · b. 1961
  • Dal-Soo KimHead of Marketing · b. 1963
  • Hee-Kyung ParkHead of Laboratory and Managing Director · b. 1966
  • Won-Yong GoHead of Information management · b. 1965
  • Ji-Hwan JangExec.
  • Jin-Haeng LeeExec.

Financials

Income Statement

Currency: KRW2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue56.28B49.80B37.70B49.44B32.34B34.04B41.45B28.64B5.92B6.96B7.39B7.70B7.95B16.27B15.60B14.17B12.25B13.20B15.05B
Growth (%)--11.52%-24.29%+31.15%-34.58%+5.26%+21.77%-30.91%-79.33%+17.59%+6.23%+4.18%+3.20%+104.61%-4.09%-9.16%-13.54%+7.71%+14.04%
Cost of Revenue52.22B47.09B36.38B44.37B31.89B33.17B38.91B27.85B1.85B2.53B3.07B3.30B2.85B5.38B4.98B4.54B4.03B4.14B6.08B
Gross Profit----454.03M873.50M2.55B786.99M4.07B4.43B4.32B4.41B5.10B10.88B10.63B9.63B8.22B9.06B8.97B
Gross Margin----1.40%2.57%6.14%2.75%68.78%63.63%58.43%57.21%64.18%66.91%68.11%67.97%67.12%68.65%59.62%
Operating Expense----7.10B4.74B4.13B5.05B4.10B5.22B7.52B8.85B2.08B5.73B6.46B8.05B10.06B10.42B12.41B
Operating Income-----6.64B-3.86B-1.58B-4.26B-31.41M-791.87M-3.20B-4.44B3.02B5.15B4.17B1.58B-1.84B-1.36B-3.44B
Operating Margin-----20.54%-11.35%-3.81%-14.87%-0.53%-11.38%-43.28%-57.62%38.02%31.65%26.70%11.16%-15.01%-10.28%-22.86%
EBITDA---------------3.46B-3.95B780.10M-258.73M
EBITDA Margin---------------24.44%-32.22%5.91%-1.72%
Net Income-----13.42B-4.04B-1.59B-7.44B-629.74M-1.56B-6.96B-4.12B3.50B4.92B4.97B2.24B-4.82B-1.94B-3.13B
Net Income Margin-----41.50%-11.87%-3.84%-25.97%-10.64%-22.38%-94.11%-53.46%44.09%30.22%31.84%15.81%-39.30%-14.73%-20.77%
R&D----1.12B363.00M408.55M------1.79B2.36B3.34B3.78B3.67B5.01B
R&D as % of Total Revenue----3.47%1.07%0.99%------11.01%15.15%23.60%30.87%27.80%33.31%
Interest Expense00000000000002.45M8.34M9.08M591.59M1.56B1.18B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.02%0.05%0.06%4.83%11.81%7.83%

Balance Sheet

Currency: KRW2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets63.42B58.67B50.68B50.28B32.90B38.31B42.42B25.51B25.64B33.02B27.90B24.08B21.79B27.23B31.91B34.67B90.91B109.61B92.94B
Total Liabilities49.49B27.73B16.54B24.39B14.97B21.65B26.48B16.58B16.73B11.92B8.06B7.77B1.58B2.16B2.07B2.98B27.34B33.57B20.50B
Total Equity13.93B30.94B34.14B25.88B17.92B16.66B15.94B8.92B8.91B21.10B19.84B16.30B20.20B25.07B29.84B31.69B63.57B76.04B72.35B
Cash504.49M367.50M26.42M1.51B800.96M2.17B2.19B1.44B-205.46M2.56B1.62B1.69B2.41B9.34B10.61B9.45B10.25B35.91B29.75B
Total Debt--------9.15B---8.27M11.60M-----
Net Debt----------------12.77B--

Cash Flow

Currency: KRW2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.37B2.15B1.50B-4.31B-1.88B-3.68B4.81B-363.21M-1.12B-2.12B1.02B1.05B4.23B6.01B3.36B36.13M346.54M-640.63M
Investing Cash Flow---2.43B294.35M-1.03B-1.73B-935.30M-6.16B1.89B-1.71B-841.51M2.92B-5.09B-4.51B-55.70B24.24B-
Financing Cash Flow2.16B-3.16B1.16B2.89B5.32B-3.80B201.20M7.47B-780.85M900.31M436.94M-18.38M6.47M-106.62M56.47B1.08B-
Capital Expenditure1.29B2.29B2.01B497.13M762.78M1.31B115.94M1.12B2.79B4.82B840.12M952.65M424.64M443.44M361.54M705.43M825.81M1.90B
Free Cash Flow------------3.81B5.57B3.00B-669.30M-479.27M-2.54B
FCF to OCF------------89.97%92.62%89.24%-1852.61%-138.30%396.78%

Earnings

Report DateMar 31, 2011Jun 30, 2011Sep 30, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Aug 16, 2016Nov 11, 2016Feb 13, 2017May 12, 2017Aug 14, 2017Nov 14, 2017Feb 13, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Jan 29, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Mar 18, 2020May 16, 2020Aug 14, 2020Nov 16, 2020Mar 19, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Mar 21, 2022Mar 31, 2022Jun 30, 2022Sep 30, 2022Mar 23, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------------------------
EPS Actual-9.849.56-6.47-40.30-35.72-106.66-55.76-9.08-37.11-80.48-32.04-10.53-37.90-1.41-22.76-7.90-21.4728.63-34.09-12.86-19.479.27-44.60-11.63-11.30-139.83-6.70-21.53-37.46-62.91-6.16-12.19123.324.086.8464.5949.7531.8145.0047.0056.005.8938.956.8529.19-5.2718.261.20-12.81-119.8913.93-89.14-1.8528.68-13.3826.83-3.64-78.91-23.6434.05
Surprise------------------------------------------------------------
Timing-------------------Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market---Pre-market--------------

Key Statistics & Ratios

Market Cap55.84B
Enterprise Value31.79B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.45
Price / Book0.68
Revenue (TTM)29.88B
Gross Profit (TTM)786.99M
Profit Margin-18.75%
Operating Margin-11.95%
Return on Equity-441.26%
Return on Assets-8.03%
Shares Outstanding32.14M
Shares Float19.49M
Beta0.83
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20041×
60.00Dec 29, 2004
20031×
15.00Dec 29, 2003
20022×
15.00Dec 27, 200223.19Jun 27, 2002
20011×
46.37Jun 28, 2001

Stock Splits

  • Oct 18, 2002455:422